OS Therapies, Inc. (OSTX): Analyst Median Target

Symbol and logo of brand OS Therapies Inc. (OSTX)

Current price action for OS Therapies Incorporated (OSTX) reflects market expectations, with the current indicator standing at 8.25. OS Therapies Incorporated unites leading oncologists to combat rare pediatric pathologies through targeted therapy. The business relies on unique patents in the field of solid tumor immunology, creating barriers to entry for competitors. Simultaneously, the company is implementing robotic systems to accelerate laboratory testing and cell culture analysis.

OSTX - OS Therapies Inc. Consensus Target over the range 08/02/2024 - 11/11/2026
Original product of OS Therapies Inc

For OS Therapies Incorporated (OSTX), whose valuation depends on the success of alliances with oncology clinics in osteosarcoma therapy, the pricing trend reflects market confidence in the pace of drug development. This consensus target, derived from market experts, is calculated as the arithmetic mean of analysts' price targets, allowing investors to track the trajectory of the asset's fair value revisions and timely identify signs that the stock is overbought or undervalued.

Competing companies

ONC - Average Forecast Price|Price Target Chart Halozyme HALO|Analyst Median Target Revolution Medicines Inc (RVMD)|AAPG: Consensus Target|CG Oncology Therapeutics - Analyst Forecast Prices|URGN (UroGen Pharma Ltd.) - Consensus Target|Broker Consensus Forecast BCAX|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|CSBR - Consensus Target|XBIT: Consensus Target|CVM - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics - Fair Value Consensus|ANL (Adlai Nortye Ltd) - Analyst Consensus Forecast|Average Forecast Price Veru Corporation VERU|Price Target Chart Tempest Therapeutics (TPST)|XLO - Average Forecast Price|Price Target Chart Renovaro RENB|Analyst Median Target Mural Oncology PLC (MURA)|KAPA: Consensus Target|Fair Value Consensus OKUR (OnKure Therapeutics Inc)|GDTC (w2.cytomed.sg) - Consensus Target|CRIS: Analyst Forecast Prices|APLM (Apollomics Inc.) - Analyst Consensus Forecast|THAR: Fair Value Consensus|Analyst Consensus Forecast ADVB|GNPX - Average Forecast Price|Price Target Chart Calidi Biotherapeutics, Inc. CLDI|Fair Value Consensus SBFM|Xenetic Bio - Analyst Consensus Forecast|SLRX - Analyst Consensus Forecast|Purple Biotech Corp (PPBT) - Price Target Chart|Forecast Levels Chart AONC (American Oncology Network, Inc.)|BGNE (BeiGene, Ltd.) - Analyst Consensus Forecast|checkpointtx.com (CKPT) - Analyst Median Target|Analyst Consensus Forecast ELEV|ICAD - Average Forecast Price|Price Target Chart Ikena Oncology IKNA|Analyst Median Target Notable Labs Corp (NTBL)|VIRX: Consensus Target|Fair Value Consensus MOR (morphosys.com)|NAYA: Analyst Consensus Forecast|AAPGV - Analyst Median Target